Comparative Pharmacology
Head-to-head clinical analysis: SILENOR versus VIVACTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SILENOR versus VIVACTIL.
SILENOR vs VIVACTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; promotes sleep by antagonizing central histaminergic neurotransmission.
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
6 mg orally once daily at bedtime, not to exceed 6 mg/day.
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours (range 8-15 hours) in healthy adults; prolonged in elderly and hepatic impairment.
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Primarily renal (approximately 60% as unchanged drug and metabolites), with 30% fecal elimination.
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant